1. ESRC Genomics Network (archive)
  2. Gengage
  3. The Human Genre Project

Egenis · Events

Egenis Seminar with Dr Nadire Ali 'Human ES and iPS cell-derived cardiomyocytes: Challenges in their potential uses in medicine'

Seminar   28.03.2011






Dr Nadire Ali, National Heart and Lung Institute, Imperial College London

Organised by



University of Exeter,Egenis,Byrne House,St Germans Road,Exeter, EX4 4PJRoom no: GF7, Byrne House

Event details

Time: 3:00 - 4:30 pm


Human ES and iPS cell-derived cardiomyocytes: Challenges in their potential uses in medicine ES cells (ESCs) and iPSCs are potentially good sources of cardiomyocytes because they can both form all cell types in the body and can be propagated for extended periods in vitro. These cells and their derivatives can be used potentially in several applications including as model systems (e.g. to study early human cardiac development, or study of specific human cardiomyopathies), as a test bed for drug toxicity assays, functional genomics studies and in future cell therapies to repair/regenerate damaged hearts. However, there are several hurdles which need to be overcome. These relate to pluripotent stem cells themselves, the methods of generating cardiomyocytes, and some aspects of the derived cardiac cells themselves. Currently ESC-derived cardiomyocytes can only be used in certain applications only. In my talk, after a brief introduction and update on ESCs and iPSCs, I will describe the various methods by which we and others have been generating cardiomyocytes from mouse and human ESC cells, highlighting the challenges that need to be overcome for more efficient generation of cardiomyocytes, and the possible solutions for this. You will be presented also with examples from some of our work that involves using these cells in various applications. Finally, I will discuss the challenges, and possible solutions for future work, regarding 1) the heterogeneity of cardiomyocytes (i.e. the fact that all cardiac subtypes are present in the differentiated cultures), 2) their purity (i.e. the presence of non-cardiac cells in these cultures), 3) their maturity, and 4) the cost of producing them.

Further details